Search results
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $94.00 at Needham & Company LLC
ETF DAILY NEWS· 3 days agoThe brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ITCI. Bank of America increased their target < ...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 4 hours agoAs a teenager growing up in northeastern Pennsylvania, she saw numerous neurologists and tried a...
Taysha Gene Therapies (NASDAQ:TSHA) Given Overweight Rating at Cantor Fitzgerald
ETF DAILY NEWS· 3 days agoCantor Fitzgerald’s target price suggests a potential upside of 135.69% from the company’s current price. JMP Securities restated a “market outperform” ...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 6 days agoOn Monday, Piper Sandler shifted its stance on Fate Therapeutics (NASDAQ:FATE) stock, raising the...
Sarepta stock soars on Duchenne gene therapy expanded approval - Boston Business Journal
The Business Journals· 2 days agoShares of Sarepta Therapeutics shot up nearly 35% when markets opened Friday, following the FDA's...
Sarepta Gains as FDA Official Overrules Staff to Approve Therapy
Bloomberg via Yahoo Finance· 2 days ago(Bloomberg) -- A top US Food and Drug Administration official overrode reviewers to give broad...
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Legend...
Benzinga· 6 days agoShares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being...
Laser Treatment for Hair Loss: A Complete Guide
AOL· 1 day agoWhile it may not be the first solution you think of, laser treatment for hair loss is a newer option for hair regrowth, and it’s safer and more tolerable than it sounds. Also referred to as ...
Sarepta Duchenne gene therapy wins broader use from FDA
BioPharma Dive via Yahoo Finance· 3 days agoThe approval makes Elevidys available to most Duchenne patients at least 4 years of age, despite...
Clarus Wealth Advisors Sells 841 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
ETF DAILY NEWS· 5 hours agoClarus Wealth Advisors lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 25.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities ...